- Sale of Duncan Facility and its related operations confirms
Harvest One's strategic transition to a cannabis-focused Consumer
Packaged Goods ("CPG") company
- Duncan Facility sale streamlines Harvest One's operating
model and significantly improves its cost structure and strengthens
balance sheet
- Licence Agreement provides Harvest One with royalty stream
for Cannabis 2.0 brands in Canada
- $1.5 million bridge financing
secured to fund working capital in advance of the closing of sale
of Duncan Facility and its related operations
VANCOUVER, BC, June 26, 2020 /CNW/ - Harvest One Cannabis Inc.
("Harvest One" or the "Company") (TSX-V:
HVT) (OTCQX: HRVOF) is pleased to announce, as part of the
Company's previously announced Strategic Review, it has entered
into a definitive agreement (the "Acquisition Agreement") to
sell its United Greeneries' licensed cannabis cultivation and
processing businesses (the "Transaction") located in
Duncan, British Columbia (the
"Duncan Facility") to Costa Canna Production Limited
Liability Partnership ("Costa LLP") and 626875 B.C. Ltd. (together with Costa LLP, the
"Purchasers") for total cash consideration of $8.2 million. Upon closing of the
Transaction, Harvest One will also effect a licence agreement with
the Purchasers, which will provide Costa LLP, through its licensed
subsidiary, with the right to use certain licensed intellectual
property of Harvest One to produce and distribute Cannabis 2.0
products in Canada in exchange for
a royalty to be paid to Harvest One and, in turn, provide Harvest
One with distribution for Cannabis 2.0 products in Canada.
"The agreement to sell our Duncan Facility and its related
operations represents a strategic step forward for Harvest One,
further divesting from its capital intensive cultivation activities
and firmly establishing ourselves as a cannabis-focused CPG
company," said Andrew Bayfield,
Chief Executive Officer of Harvest One. "We will continue to focus
on expanding our core brands of LivRelief™, Dream Water™ and
Satipharm together with the commercialization of Cannabis 2.0
product offerings in Canada."
Mr. Bayfield continued, "When complete, this Transaction will
significantly improve the Company's overall cost structure and will
provide liquidity to strengthen our balance sheet. We are
continuing to take necessary and decisive measures to streamline
our operations, lower our cost structure and reduce our cash burn.
I am confident we are on the right path and this Transaction serves
to further reinforce the Company's plan to become cash flow
positive in fiscal 2021."
Terms of the Acquisition Agreement
Under the terms of the Acquisition Agreement the Company will
sell all of the facilities, licences and assets comprising its
United Greeneries' cannabis cultivation and processing businesses
in Duncan, British Columbia, for
total cash consideration of $8.2
million. The Purchasers will also issue to the Company's
subsidiary, two promissory notes representing the value of
certain existing cannabis and cannabis-related item inventories, to
be calculated at closing. The Transaction is subject to a number of
conditions, including the receipt of certain regulatory clearances
and consents and the satisfaction or waiver of all conditions of
closing under the Acquisition Agreement. The Transaction is
anticipated to close on or around July 30,
2020.
Harvest One will retain all intellectual property associated
with its Cannabis 2.0 product portfolio including, the Company's
LivReliefTM cannabis-infused topicals currently on sale
in British Columbia, Alberta, Saskatchewan, Manitoba and Ontario.
Licence Agreement
Upon closing of the Transaction, Harvest One, through its
wholly-owned subsidiaries, Dream Products Inc., Delivra Corp. and
United Greeneries Holdings Ltd. (the "Subsidiaries"), will
effect a licence agreement (the "Licence Agreement") with
United Greeneries Ltd. ("United Greeneries") and Costa LLP.
Under the terms of the Licence Agreement, United Greeneries, which
will be owned by Costa LLP upon closing of the Transaction,
will license and use certain intellectual property (the
"Licence") owned by Harvest One, to produce and distribute
various cannabis products including, cannabis topicals (notably
Delivra's cannabis-infused LivReliefTM topical
creams currently available in five provinces across Canada), cannabis extracts (including, but not
limited to, cannabis vaping products), and cannabis edibles. In
consideration of the Licence, the Purchasers will pay Harvest One a
royalty in an amount equal to 95% of the revenue generated in
relation to the Licence, less certain marked-up costs and expenses
incurred by the Purchasers.
Increased Focus on Consumer Brands
With the sale of the Duncan Facility and its related operations,
the Company can enhance its focus on its leading CPG brands
LivReliefTM, Dream Water™ and Satipharm while leveraging
its core capabilities of product development and distribution.
Harvest One will continue to accelerate the commercialization of
both infused and non-infused over-the-counter consumer products
while leveraging its established distribution channels in
North America and Europe and seeking additional partnerships to
leverage the value of its portfolio of brands.
Improved Balance Sheet and Liquidity
The sale of the Duncan Facility and operations will provide an
immediate infusion of capital which will contribute to a reduction
in outstanding debt load as well as result in further reductions in
overhead expenses. Combined with recent improvements to the overall
cost structure, this will contribute to improved cash flow
capabilities for the Company.
Asset-Light Operating Model
Through the Company's new asset-light operating model, the
Company will concentrate on its core capabilities while outsourcing
a significant portion of its operations, including the sourcing of
raw materials and contract manufacturing. The repositioned Company
will be a leaner, more efficient organization focused on the
higher-margin segments of the cannabis value chain.
Bridge Financing Facility
In conjunction with the Acquisition Agreement, Harvest One has
secured a $1.5 million bridge
financing facility (the "Bridge Facility") from Costa LLP
which will be made available to the Company upon signing the
Acquisition Agreement. It is the intention of the parties that the
Bridge Facility will mature and be repaid in full upon the closing
of the Transaction. The Bridge Facility is secured by general
security agreements over the Company's, and its United Greeneries
subsidiaries', assets (the "Assets"), as well as guarantees
provided by the United Greeneries subsidiaries. In order to
facilitate the availability of the Bridge Facility, MMJ Group
Holdings Limited has agreed to subordinate its security interest in
certain of the Assets, to Costa LLP. The Bridge Facility carries a
commitment fee of $25,000 and, if not
repaid in full upon closing of the Transaction, shall bear interest
at a rate of 10% per annum.
Third Quarter Financial Results
The Company today also announced its financial and operating
results for the three and nine months ended March 31, 2020.
Third Quarter Financial Highlights
- Net revenue of $3.3 million for
the three months ended March 31,
2020, representing an 88% increase over the previous
quarter, and a 10% increase over the same period in 2019;
- Adjusted earnings (loss) before interest, taxes, depreciation
and amortization ("Adjusted
EBITDA")(1) of ($2.4) million compared to ($5.0) million in the previous quarter
representing a 51% improvement, and a 26% improvement over the same
period in 2019;
- Reduction of cash operating expenses by $1.1 million or 22% from the previous quarter as
a result of cost savings initiatives implemented; and
- Net loss of $35.4 million, which includes the impact of
$27.5 million in non-cash goodwill
impairment charges and $1.5 million
in non-cash inventory write-downs.
Summary of Key Financial Results
|
Three months ended
March 31
|
|
Nine months ended
March 31
|
|
Select Financial
Information
|
2020
|
|
2019
|
|
2020
|
|
2019
|
|
($000's, except
share and per share amounts)
|
$
|
|
$
|
|
$
|
|
$(1)
|
|
Net
revenue
|
3,328
|
|
3,023
|
|
9,160
|
|
8,444
|
|
Gross (loss)
profit
|
(1,030)
|
|
207
|
|
301
|
|
1,912
|
|
Expenses
|
5,671
|
|
5,308
|
|
18,275
|
|
15,711
|
|
Loss from
operations
|
(6,701)
|
|
(5,101)
|
|
(17,974)
|
|
(13,799)
|
|
Net loss
|
(35,410)
|
|
(5,131)
|
|
(56,995)
|
|
(14,258)
|
|
Net loss per share –
basic and diluted
|
(0.16)
|
|
(0.03)
|
|
(0.26)
|
|
(0.08)
|
|
Weighted average
number of common shares
|
214,753,073
|
|
182,215,534
|
|
214,497,526
|
|
177,789,938
|
|
Adjusted
EBITDA(1)
|
(2,441)
|
|
(1,591)
|
|
(10,854)
|
|
(8,866)
|
|
Financial Commentary
Net revenue showed sequential growth of 88% quarter-over-quarter
mainly due to a $1.6 million increase
in our cultivation division from higher recreational cannabis and
bulk cannabis sales, and fewer sales discounts and return
provisions following a weak second quarter due to industry-wide
factors. Our consumer division remained steady with a 2% decrease
quarter-over-quarter despite the economic impact of COVID-19 in the
latter part of the quarter. Net loss was impacted significantly by
$27.5 million in non-cash goodwill
impairment charges and $1.5 million
in non-cash inventory write-downs.
Adjusted EBITDA(1) loss
decreased quarter-over-quarter from ($5.0)
million to ($2.4) million
representing a significant improvement of 51%. This increase was
primarily due to increased revenues as described above and ongoing
efforts to reduce expenses, including a substantial reduction in
headcount, professional and consulting services, rent and travel
costs resulting in overall improvements in cash operating
expenses.
Outlook and Strategic Review Update
Management's outlook for sales volumes for both the consumer and
medical divisions remain promising for the remainder of fiscal 2020
and into fiscal 2021 despite industry and economic headwinds.
Cannabis 2.0 sales will be reflected in our fiscal Q4 2020 results
as we continue to see strong demand from both our retail and
provincial partners. The Company continues to focus on reducing
overhead costs and is expected to report cash cost savings in
fiscal Q4 2020 results compared to the same period a year ago.
The previously announced Strategic Review remains ongoing, as
the Company continues to evaluate all strategic alternatives and
potential sales of additional non-essential assets including the
sale of the Company's 50.1% interest in Greenbelt Greenhouse and
the Lucky Lake facility. The
Company will continue to evaluate all transactions or financing
alternatives available to support the growth and expansion of its
CPG brands and product lines.
About Harvest One
Harvest One is a global company that develops and distributes
premium health, wellness and self-care products with a market focus
on sleep, pain, and anxiety. Harvest One is a uniquely positioned
company in the cannabis space with a focus on infused and
non-infused consumer packaged goods. Harvest One owns and
operates three subsidiaries; Satipharm (medical and
nutraceutical); Dream Water Global, and Delivra (consumer); as well
as a controlling interest in Greenbelt Greenhouse. For more
information, please visit www.harvestone.com.
Non-IFRS Measures, Reconciliation and Discussion
This press release contains references to "Adjusted EBITDA",
which is a non-IFRS financial measure.
Adjusted EBITDA is a measure of the Company's overall financial
performance and is used as an alternative to earnings or net income
in some circumstances. Adjusted EBITDA is essentially net income
(loss) with from operations before interest, taxes, depreciation
and amortization and adjusted for share-based compensation, common
shares issued for services, the fair value effects of accounting
for biological assets and inventories, asset impairment and
write-downs and other non-cash items. This measure can be used to
analyze and compare profitability among companies and industries,
as it eliminates the effects of financing and capital expenditures.
It is often used in valuation ratios and can be compared to
enterprise value and revenue. This measure does not have any
standardized meaning according to IFRS and therefore may not be
comparable to similar measures presented by other companies.
There are no comparable IFRS financial measures presented in
Harvest One's financial statements. Reconciliations of the
supplemental non-IFRS measures will be presented in the Company's
management's discussion and analysis for the three and nine months
ended March 31, 2020. These non-IFRS
financial measures are presented because management has evaluated
the financial results both including and excluding the adjusted
items and believe that the non-IFRS financial measures presented
provide additional perspective and insights when analyzing the core
operating performance of the business. The Company believes
that these supplemental measures provide information useful to
shareholders and investors in understanding our performance and may
assist in the evaluation of the Company's business relative to that
of its peers.
These non-IFRS financial measures should not be considered
superior to, as a substitute for, or as an alternative to, and
should be considered in conjunction with, the IFRS financial
measures presented in the Company's financial statements. For more
information, please see "Adjusted EBITDA" and "Non-GAAP
Measures" in the Company's management's discussion and
analysis for the three and nine months ended March 31, 2020, which is available on
www.sedar.com.
Notes:
- This is a non-IFRS reporting measure. For a reconciliation of
this to the nearest IFRS measure, see "Adjusted EBITDA" and
"Non-GAAP Measures" in the Company's management discussion and
analysis for the three and nine months ended March 31, 2020, filed on SEDAR.
Cautionary Note Regarding Forward-Looking Statements
Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or future performance about Harvest One and its business and
operations, which include, among other things, statements with
respect to the closing of the Transaction, the Strategic Review,
its corporate strategy moving forward, any transactions arising
from the Strategic Review, certain financial operating metrics and
financial results, and future opportunities available for the
Company. The use of any of the words "could", "intend", "expect",
"believe", "will", "projected", "estimated" and similar expressions
and statements relating to matters that are not historical facts
are intended to identify forward-looking information and are based
on the Company's current belief or assumptions as to the outcome
and timing of such future events. Actual future results may
differ materially. The forward-looking information contained in
this press release is made as of the date hereof, and the Company
is not obligated to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise, except as required by applicable securities laws.
Because of the risks, uncertainties and assumptions contained
herein, investors should not place undue reliance on
forward-looking information. The foregoing statements expressly
qualify any forward-looking information contained herein.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accept responsibility for the adequacy or
accuracy of this release.
SOURCE Harvest One Cannabis Inc.